Pharma-Bio Serv, Inc. (PBSV)
OTCMKTS · Delayed Price · Currency is USD
0.4500
0.00 (0.00%)
At close: Oct 22, 2026
Pharma-Bio Serv Financials Overview
Financials in millions USD. Fiscal year is November - October.
Millions USD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Revenue Revenue Growth | 9.48 | 9 | 9.51 | 16.98 | 19.4 | 20.12 |
Revenue Growth | 3.25% | -5.34% | -43.99% | -12.48% | -3.56% | -6.72% |
Gross Profit Gross Profit Growth | 3.07 | 2.91 | 2.52 | 5.07 | 4.88 | 5.36 |
Operating Income Operating Income Growth | -0.15 | -0.64 | -1.29 | 1.12 | 1.17 | -3.85 |
Net Income Net Income Growth | 0.25 | -0.1 | -0.78 | 1.31 | 1.01 | -2.09 |
Earnings Per Share EPS Growth | 0.01 | -0.00 | -0.03 | 0.06 | 0.04 | -0.09 |
EPS Growth | - | - | - | 30.25% | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Puerto Rico Consulting Puerto Rico Consulting Growth | 5.14 | 4.64 | 5.69 | 8.04 | 12.14 | 14.68 |
United States Consulting United States Consulting Growth | 2.52 | 2.62 | 3.16 | 4.67 | 4.56 | 2.72 |
Europe Consulting Europe Consulting Growth | 1.81 | 1.73 | 0.57 | 4.26 | 2.65 | 2.33 |
Other Other Growth | 0 | 0.02 | 0.09 | 0.01 | 0.05 | 0.38 |
Total Total Growth | 9.48 | 9 | 9.51 | 16.98 | 19.4 | 20.12 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Cash & Investments Cash & Investments Growth | 8.58 | 10.85 | 12.75 | 14.98 | 14.46 | 17.47 |
Total Debt Total Debt Growth | - | 0.03 | 0.19 | 0.35 | 0.49 | 0.62 |
Net Cash (Debt) Net Cash Growth | 8.58 | 10.83 | 12.55 | 14.63 | 13.98 | 16.85 |
Net Cash Growth | -19.49% | -13.75% | -14.21% | 4.69% | -17.07% | 16.91% |
Net Cash Per Share Net Cash Per Share Growth | 0.37 | 0.47 | 0.55 | 0.64 | 0.61 | 0.73 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -0.41 | -0.21 | -0.57 | 1.89 | 0.59 | 0.8 |
Capital Expenditures CapEx Growth | -0.01 | -0.01 | -0.16 | -0.01 | -0.02 | -0.01 |
Free Cash Flow Free Cash Flow Growth | -0.42 | -0.22 | -0.73 | 1.88 | 0.57 | 0.79 |
Free Cash Flow Growth | - | - | - | 228.64% | -27.81% | -45.57% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Gross Margin | 32.32% | 32.33% | 26.46% | 29.84% | 25.16% | 26.65% |
Operating Margin | -1.63% | -7.08% | -13.54% | 6.58% | 6.06% | -19.16% |
Pretax Margin | 2.84% | -1.05% | -7.94% | 9.94% | 6.13% | -9.33% |
Profit Margin | 2.65% | -1.12% | -8.18% | 7.72% | 5.19% | -10.39% |
FCF Margin | -4.44% | -2.46% | -7.64% | 11.10% | 2.96% | 3.95% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 25, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
PE Ratio | 41.00 | - | - | 14.89 | 19.60 | - |
Forward PE | 4.50 | 4.91 | 5.27 | 7.73 | 13.23 | 12.12 |
P/FCF Ratio | - | - | - | 10.36 | 34.42 | 29.87 |
PS Ratio | 1.09 | 1.38 | 1.40 | 1.15 | 1.02 | 1.18 |